A study published in Drug Safety found that nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from regulatory agencies. To address this, researchers created a safety checklist that includes important warnings for these drugs. The checklist covers contraindications, boxed warnings, and special warnings for various conditions. The study also highlighted surprising findings, such as certain drugs not having warnings for specific adverse events. The researchers suggest that the checklist be regularly updated as new information emerges to help rheumatology trainees and specialists navigate the risks associated with these drugs.
Source link
Safety checklist compiles clinically important DMARD warnings in one place
